Literature DB >> 9633515

The human papillomavirus type 16 E5-protein modulates ligand-dependent activation of the EGF receptor family in the human epithelial cell line HaCaT.

K Crusius1, E Auvinen, B Steuer, H Gaissert, A Alonso.   

Abstract

The E5 open reading frame of the human papillomavirus type 16 encodes a transmembrane protein associated with the Golgi, ER, and plasma membranes. We have analyzed the effect of E5 expression on the activation of the EGF receptor family. We find that expression of the E5-protein strongly enhances EGFR activation in a ligand-dependent manner. This activation takes place immediately after addition of ligand, demonstrating that increased tyrosine phosphorylation cannot solely be due to an impaired downregulation of the receptors. Furthermore, this activation is not a result of impaired activity of EGFR-specific phosphatase through the E5-protein, as demonstrated by using inhibitors specifically blocking EGFR activation. In addition, treatment with EGF results in an enhanced activation of the ErbB2 receptor in E5-expressing cells. This superactivation must be a result of heterodimer formation between EGFR and ErbB2, since EGF is not a ligand for ErbB2. Finally, treatment of E5-expressing cells with HB-EGF shows no increased phosphorylation of the ErbB4 receptor, suggesting a specific effect of E5 on the activation of the different members of the EGFR family.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9633515     DOI: 10.1006/excr.1998.4024

Source DB:  PubMed          Journal:  Exp Cell Res        ISSN: 0014-4827            Impact factor:   3.905


  45 in total

1.  Human papillomavirus type 31 E5 protein supports cell cycle progression and activates late viral functions upon epithelial differentiation.

Authors:  Frauke Fehrmann; David J Klumpp; Laimonis A Laimins
Journal:  J Virol       Date:  2003-03       Impact factor: 5.103

2.  The human papillomavirus type 16 E5 oncoprotein inhibits epidermal growth factor trafficking independently of endosome acidification.

Authors:  Frank A Suprynowicz; Ewa Krawczyk; Jess D Hebert; Sawali R Sudarshan; Vera Simic; Christopher M Kamonjoh; Richard Schlegel
Journal:  J Virol       Date:  2010-08-04       Impact factor: 5.103

3.  A role for HPV16 E5 in cervical carcinogenesis.

Authors:  John P Maufort; Anny Shai; Henry C Pitot; Paul F Lambert
Journal:  Cancer Res       Date:  2010-03-23       Impact factor: 12.701

4.  Membrane orientation of the human papillomavirus type 16 E5 oncoprotein.

Authors:  Ewa Krawczyk; Frank A Suprynowicz; Sawali R Sudarshan; Richard Schlegel
Journal:  J Virol       Date:  2009-12-02       Impact factor: 5.103

Review 5.  Promising systemic immunotherapies in head and neck squamous cell carcinoma.

Authors:  Neil Gildener-Leapman; Robert L Ferris; Julie E Bauman
Journal:  Oral Oncol       Date:  2013-10-11       Impact factor: 5.337

6.  The human papillomavirus type 16 E5 protein impairs TRAIL- and FasL-mediated apoptosis in HaCaT cells by different mechanisms.

Authors:  Kirsten Kabsch; Angel Alonso
Journal:  J Virol       Date:  2002-12       Impact factor: 5.103

7.  HPV 16 E5 oncoprotein is expressed in early stage carcinogenesis and can be a target of immunotherapy.

Authors:  Francesca Paolini; Gianfranca Curzio; Marcelo Nazario Cordeiro; Silvia Massa; Luciano Mariani; Fulvia Pimpinelli; Antonio Carlos de Freitas; Rosella Franconi; Aldo Venuti
Journal:  Hum Vaccin Immunother       Date:  2016-12-08       Impact factor: 3.452

Review 8.  Human papillomavirus-16 E5 protein: oncogenic role and therapeutic value.

Authors:  Niladri Ganguly
Journal:  Cell Oncol (Dordr)       Date:  2012-01-20       Impact factor: 6.730

9.  Quantitative measurement of human papillomavirus type 16 e5 oncoprotein levels in epithelial cell lines by mass spectrometry.

Authors:  Ziad Sahab; Sawali R Sudarshan; Xuefeng Liu; YiYu Zhang; Alexander Kirilyuk; Christopher M Kamonjoh; Vera Simic; Yuhai Dai; Stephen W Byers; John Doorbar; Frank A Suprynowicz; Richard Schlegel
Journal:  J Virol       Date:  2012-06-27       Impact factor: 5.103

10.  Cellular entry of human papillomavirus type 16 involves activation of the phosphatidylinositol 3-kinase/Akt/mTOR pathway and inhibition of autophagy.

Authors:  Zurab Surviladze; Rosa T Sterk; Sergio A DeHaro; Michelle A Ozbun
Journal:  J Virol       Date:  2012-12-19       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.